

1

2

3 The ER membrane chaperone Shr3 acts in a progressive manner to  
4 assist the folding of related plasma membrane transport proteins

5

6

7

8

9 Ioanna Myronidi<sup>§</sup>, Andreas Ring<sup>§</sup> and Per O. Ljungdahl\*

10

11

12 *Department of Molecular Biosciences, The Wenner-Gren Institute, SciLifeLab, Stockholm*  
13 *University, SE-106 91, Sweden*

14

15

16 Running title: Membrane-localized chaperone substrate interactions

17

18

19 Keywords: Shr3; membrane-localized chaperone; amino acid permease; polytopic membrane  
20 protein folding; endoplasmic reticulum; *Saccharomyces cerevisiae*

21

22 <sup>§</sup> Contributed equally, the names are listed in alphabetic order.

23 \* Corresponding author. Mailing address: SciLifeLab, Box 1031, SE- 171 21 Solna, Sweden.

24 Phone: 46 8 16 41 01. E-mail: [per.ljungdahl@scilifelab.se](mailto:per.ljungdahl@scilifelab.se).

25

26

## 27 **Abstract**

28 Proteins with multiple membrane-spanning segments (MS) co-translationally insert into the  
29 endoplasmic reticulum (ER) membrane of eukaryotic cells. In *Saccharomyces cerevisiae*, Shr3  
30 is an ER membrane-localized chaperone that is specifically required for the functional  
31 expression of amino acid permeases (AAP), a family of eighteen transporters comprised of 12  
32 MS. Here, comprehensive scanning mutagenesis and deletion analysis of Shr3, combined with  
33 a modified split-ubiquitin approach, were used to probe chaperone-substrate interactions with  
34 seven different AAP *in vivo*. Our findings indicate that Shr3 specifically recognizes AAP  
35 substrates, largely independent of sequence-specific interactions involving membrane and  
36 lumenally oriented domains. Shr3 selectively and robustly interacts with nested C-terminal AAP  
37 truncations in marked contrast to similar truncations of non-Shr3 substrate polytopic sugar  
38 transporters. Strikingly, Shr3-AAP interactions initiate with the first 4 MS of AAP and  
39 successively strengthen, but abruptly weaken when all 12 MS are present. The data are  
40 consistent with Shr3 acting in a temporal manner as a scaffold preventing AAP translation  
41 intermediates from engaging in non-productive interactions.

42

## 43 **Introduction**

44 The integration and concomitant folding of membrane proteins in the lipid bilayer of the  
45 endoplasmic reticulum (ER) are critical steps in the biogenesis of transport proteins destined to  
46 function at the plasma membrane (PM). Most eukaryotic membrane proteins are co-  
47 translationally inserted into the ER membrane via the Sec61-complex, also known as the  
48 translocon. The translocon forms a protein-conducting channel that mediates protein  
49 translocation and the co-translational partitioning of membrane-spanning segments (MS)  
50 (Johnson and van Waes, 1999; Rapoport et al., 2017; Seinen and Driessen, 2019). During the  
51 synthesis of complex polytopic membrane proteins comprised of multiple MS, each MS  
52 sequentially exits the channel and partitions into the ER membrane via the lateral gate of the  
53 translocon. Although the central channel of the translocon is too small to accommodate multiple  
54 MS, the translocon appears to have a limited capacity to promote the folding of membrane  
55 proteins comprised of up to three MS; two separate extra-channel MS-binding sites have been  
56 reported to act in a chaperone-like manner to delay the release of N-terminal MS until  
57 translation is completed (Hou et al., 2012). However, as the complexity of membrane proteins  
58 grows beyond three MS, the challenge of preventing inappropriate interactions between  
59 incompletely translated nascent chains apparently exceeds the chaperone-like activity of the  
60 translocon. Specifically, during the translation of complex polytopic membrane proteins, e.g.,  
61 amino acid permeases with 12 MS, the N-terminal MS partition into the membrane prior to the  
62 synthesis and partitioning of C-terminal MS. To prevent the MS of translation intermediates  
63 from entering non-productive folding pathways, discrete and highly specialized ER resident

64 membrane proteins have been described in fungi that prevent misfolding of specific families of  
65 polytopic membrane proteins (Kota and Ljungdahl, 2005; Lau et al., 2000; Ljungdahl et al.,  
66 1992; Luo et al., 2002; Martínez and Ljungdahl, 2000; 2004; Sherwood and Carlson, 1999;  
67 Shurtleff et al., 2018).

68 Shr3, the most comprehensively studied of these specialized ER components, was  
69 identified as an integral membrane protein required for the functional expression of the  
70 conserved family of amino acid permeases (AAP) (Ljungdahl *et al.*, 1992). The AAP family in  
71 *Saccharomyces cerevisiae*, belonging to the Amino acid-Polyamine-Organocation (APC)  
72 super-family of transporters (Gilstring and Ljungdahl, 2000; Jack et al., 2000; Saier, 2000;  
73 Wong et al., 2012), is comprised of 18 genetically distinct but structurally similar proteins with  
74 12 MS. Shr3 is composed of 210 amino acids organized into two functional domains; a N-  
75 terminal membrane domain comprised of four hydrophobic  $\alpha$ -helices connected by three  
76 hydrophilic loops and a hydrophilic cytoplasmically oriented C-terminal domain. Initially, Shr3  
77 was recognized as an essential factor facilitating the packaging of AAP into ER-derived  
78 secretory vesicles (Kuehn et al., 1996), and it was found to be important for the proper  
79 presentation of ER-exit motifs, located within the hydrophilic C-terminal tails of AAP, to the  
80 inner COPII coatomer subunit Sec24 (Kuehn et al., 1998; Malkus et al., 2002; Miller et al.,  
81 2002; Miller et al., 2003). Additional data regarding the packaging activity of Shr3 included  
82 genetic and physical interactions of Shr3 with components of the COPII-coated vesicles  
83 (Gilstring et al., 1999). Also, it was shown that Shr3 facilitated ER-vesicle formation in close  
84 proximity to fully integrated and folded AAP (Gilstring and Ljungdahl, 2000; Gilstring *et al.*,  
85 1999) and hence Shr3 was designated a packaging chaperone. The ability of Shr3 to interact  
86 with COPII components is primarily linked to its hydrophilic C-terminal tail. Consistently, Shr3  
87 was found to associate with newly synthesized Gap1 in a transient manner, the interaction was  
88 reported to exhibit a half-life of approximately 15 min. The observed association with Gap1  
89 was initially thought to occur post-translationally since Gap1 fully integrates into the ER-  
90 membrane with each MS correctly oriented independently of Shr3 (Gilstring and Ljungdahl,  
91 2000). Also, the AAP that accumulate in the ER of *shr3* $\Delta$  strains do not activate the unfolded  
92 protein stress response (UPR) (Gilstring *et al.*, 1999).

93 However, subsequent studies revealed that Shr3 has an important function that is separate  
94 from and precedes its packaging function. Consequently, the view of Shr3 evolved from being  
95 a packaging into a specialized membrane-localized chaperone that interacts early with substrate  
96 AAP during their co-translational insertion into the ER membrane (Kota et al., 2007; Kota and  
97 Ljungdahl, 2005). In these studies, Shr3 was found to prevent the aggregation of AAP in the  
98 ER-membrane, a function associated with its N-terminal membrane domain (Kota and  
99 Ljungdahl, 2005). Critical evidence demonstrating the importance of Shr3 in facilitating the  
100 folding of AAP includes the finding that co-expressed split N- and C-terminal portions of Gap1  
101 assemble into a functional permease in a Shr3-dependent manner (Kota *et al.*, 2007). The

102 membrane domain of Shr3 is required and suffices to prevent aggregation of the first five MS  
103 of Gap1 enabling productive folding interactions with the C-terminal portions of Gap1. Similar  
104 to full-length Gap1, the N-terminal fragment displays an increased propensity to aggregate in  
105 membranes isolated from cells lacking Shr3, and importantly, its aggregation appeared not to  
106 be affected by the presence or absence of the C-terminal fragment. In marked contrast, the  
107 aggregation status of the C-terminal fragment was dependent on the presence of both Shr3 and  
108 the N-terminal fragment. Since the N- and C-terminal fragments individually insert into the  
109 membrane, Shr3 apparently can maintain the N-terminal fragment in a conformation that  
110 enables the C-terminal fragment to interact and assemble with it. Although direct physical  
111 interactions between Shr3 and substrate AAP have not been demonstrated, all available data is  
112 consistent with Shr3 interacting early with N-terminal MS as they co-translationally partition  
113 into the ER membrane.

114 During translocation, exclusively hydrophobic MS partition readily into the lipid phase of  
115 the membrane, whereas less hydrophobic MS containing (Heinrich et al., 2000) charged or  
116 polar residues partition into the membrane less readily and are retained in proximity to the  
117 translocon or to translocon associated proteins, e.g., TRAM (Heinrich and Rapoport, 2003). In  
118 analogy to TRAM, we posited that Shr3 facilitates the partitioning of MS of AAP containing  
119 charged or polar amino acid residues as they emerge from the translocon. According to this  
120 hypothesis, Shr3 may physically shield charged or polar residues within MS, thereby preventing  
121 these thermodynamically challenging segments from engaging in nonproductive interactions  
122 (Kota *et al.*, 2007). More recent findings in yeast regarding the conserved ER membrane protein  
123 complex (EMC) have been interpreted in a similar manner (Miller-Vedam et al., 2020; Shurtleff  
124 *et al.*, 2018). However, a striking difference between Shr3 and EMC function is that null alleles  
125 of *SHR3* do not activate the UPR (Gilstring *et al.*, 1999).

126 Despite the clear requirement of Shr3 in AAP biogenesis, we currently lack critical  
127 information regarding the mechanisms underlying Shr3 function. Here we have focused on the  
128 membrane domain of Shr3 and employed a comprehensive scanning mutagenesis approach to  
129 define amino acid residues involved in recognizing AAP substrates. Further, we have exploited  
130 a split-ubiquitin approach to directly probe and characterize interactions with seven different  
131 AAP substrates *in vivo*. The data support Shr3 acting as a MLC providing a scaffold-like  
132 structure to help nascent chains of partially translated AAP maintain a structure required to  
133 enter and follow a productive folding pathway as translation proceeds to completion.

134

## 135 **Results**

### 136 **Systematic scanning mutagenesis of MS within the membrane domain of Shr3**

137 We have previously shown that the membrane domain of Shr3 is required and sufficient for  
138 facilitating the folding of AAPs (Kota and Ljungdahl, 2005). Here, a systematic scanning  
139 mutagenesis approach was used to identify residues within the Shr3 membrane domain required  
140 for function. Intramembrane residues were mutated to leucine; the length of consecutive  
141 substitution mutations varied, ranging from 2 to 13 residues. The extramembrane residues  
142 within ER lumenal loops L1 and L3 and cytoplasmic oriented NT and loop L2 were mutated  
143 to alanine; the length of consecutive alanine replacements ranged from 2 to 3.

144 The biological activity of the mutant proteins was initially assessed using growth-based  
145 assays on YPD supplemented with metsulfuron-methyl (MM), which provides a sensitive  
146 measure of Shr3 function. MM targets and inhibits branched-chain amino acid synthesis and  
147 growth is strictly dependent on the combined activity of multiple SPS-sensor regulated AAP  
148 that facilitate high-affinity isoleucine, leucine and valine uptake (Andréasson and Ljungdahl,  
149 2002; Jørgensen et al., 1998). Serial dilutions of cell suspensions from strain JKY2 (*shr3Δ*)  
150 carrying vector control (VC), *SHR3* or the *shr3* mutant alleles were spotted on YPD and  
151 YPD+MM plates (Supplementary Material Fig. S1 – S10). Only three mutant alleles, *shr3-35*,  
152 *shr3-50* and *shr3-76*, failed to support growth (Fig. 1A and B). The steady state levels of the  
153 three mutant proteins were similar to wildtype Shr3 (Fig. 1B), suggesting that the mutant  
154 proteins were not grossly misfolded, and consequently, not prematurely targeted for ER-  
155 associated degradation.

156 The *shr3-35* allele encodes a protein with residues 17 through 19 (serine-alanine-threonine)  
157 in MS I replaced by leucine (Fig. 1A). To more precisely define the critical residues, we  
158 constructed additional mutant alleles with paired leucine substitutions at residues 17-18 (LLT),  
159 18-19 (SLL), and 17 and 19 (LAL). Expression of *SHR3-36* (LLT) and *SHR3-38* (LAL) alleles  
160 complemented *shr3Δ* and supported wildtype growth on YPD + MM (Fig. 1C, dilutions 4 and  
161 6). By contrast, cells expressing *shr3-37* (SLL) did not complement, exhibiting a phenotype  
162 similar to the *shr3-35* (LLL) mutant (Fig. 1C, dilutions 3 and 5).

163 The *shr3-76* allele carries leucine replacements at residues 139 through 142 (serine-  
164 asparagine-isoleucine-isoleucine) in MS IV (Fig. 1A). Again, the importance of the affected  
165 residues was tested by creating alleles with paired leucine substitutions at positions 139-140  
166 (LLII) and 141-142 (SNLL). Cells expressing *shr3-77* (LLII) allele grew poorly, although  
167 slightly better than cells expressing the *shr3-76* allele (Fig. 1C, dilutions 15 and 16). Cells  
168 expressing *SHR3-78* (SNLL) grew as wildtype *SHR3* (Fig. 1C, dilutions 14 and 17).

169 The third non-functional allele, *shr3-50*, encodes a mutant protein with alanine  
170 substitutions at residues 51 through 53 (leucine-arginine-histidine) located within the ER  
171 lumenal loop L1 (Fig. 1A). The importance of these residues was tested by paired alanine  
172 substitutions of the positions 51-52 (AAH), 52-53 (LAA), and 51 and 53 (ARA). Expression of  
173 these alleles demonstrated that *SHR3-51* (AAH) and *SHR3-52* (LAA) complemented *shr3Δ*

174 similar to wildtype *SHR3* (Fig.1C, dilutions 8, 10 and 11). The *shr3-53* (ARA) allele exhibited  
175 reduced growth (Fig. 1C, dilution 12), indicative of compromised function. The finding that  
176 mutations affecting residues 53-55 in the ER lumenal loop L1 abolish function suggests that  
177 extramembrane sequences are important for guiding the folding of AAP sequences destined to  
178 be oriented towards the extracellular side of the PM.

179

### 180 **Deletion analysis of ER-lumen oriented loops**

181 The possibility that Shr3 engages and interacts with its substrate AAP through contacts with  
182 extramembrane sequences prompted us to specifically test the functional significance of loops  
183 L1 and L3 (Fig. 2A). The residues 44-57 within L1 are predicted to fold into an amphipathic  $\alpha$ -  
184 helix (Fig. 2B). We constructed four internal deletions in L1 that affect this secondary structure  
185 motif to varying extent: *shr3 $\Delta$ 90* ( $\Delta$ 34-48); *shr3 $\Delta$ 91* ( $\Delta$ 39-47); *shr3 $\Delta$ 92* ( $\Delta$ 44-54); and *shr3 $\Delta$ 93*  
186 ( $\Delta$ 55-60). Also, an internal deletion in L3 was constructed: *SHR3 $\Delta$ 94* ( $\Delta$ 121-127). The five  
187 deletion alleles directed the expression of mutant proteins at levels comparable to *SHR3* (Fig.  
188 2C); the deletions do not decrease the steady state levels of protein. The function of these  
189 deletion alleles was assessed as before using YPD + MM. We also extended the analysis with  
190 more nuanced growth-based assays capable of monitoring amino acid uptake catalyzed  
191 predominantly by a single or a couple of AAP. This was accomplished by examining growth  
192 on minimal media individually supplemented with toxic amino acid analogues D-histidine, L-  
193 canavanine, and azetidine-2-carboxylate (AzC), which are taken up by Gap1 (Gresham et al.,  
194 2010), Can1 (Ono et al., 1983), Agp1/Gnp1 (Andréasson et al., 2004), respectively. The  
195 expression of functional alleles of *SHR3* results in impaired growth in the presence of these  
196 toxic analogues. Serial dilutions of cell suspensions from strain JKY2 (*shr3 $\Delta$* ) carrying vector  
197 control (VC), *SHR3*, *shr3 $\Delta$ 90*, *shr3 $\Delta$ 91*, *shr3 $\Delta$ 92*, *shr3 $\Delta$ 93* or *SHR3 $\Delta$ 94* were spotted on SAD  
198 containing D-histidine, SD + L-canavanine, SD + AzC, and YPD + MM plates. The four  
199 internal deletion alleles affecting L1 failed to complement *shr3 $\Delta$* ; the strains grew similar as  
200 the VC (Fig. 2C, dilutions 1, 3, 4, 5 and 6). By contrast, the strain expressing the internal  
201 deletion in L3 showed a more complex pattern of growth. On SAD + D-histidine and SD + L-  
202 canavanine, *SHR3 $\Delta$ 94* appeared to express a non-functional protein, the strain grew in the  
203 presence of these toxic amino acid analogues (Fig. 2C, compare dilution 1 with 7). However,  
204 on SD + AzC and YPD + MM, the *SHR3 $\Delta$ 94* allele exhibited growth similar to wildtype *SHR3*  
205 (Fig. 2C, compare dilution 2 with 7). Note that on YPD + MM the strain carrying *SHR3 $\Delta$ 94*  
206 exhibited enhanced growth compared to wildtype, and consequently, on YPD + MM we  
207 designated the phenotype WT<sup>+</sup>.

208

### 209 **Lumenal loop L3 influences substrate specificity**

210 The finding that *SHR3Δ94* exhibited a range of phenotypes, i.e., from null to apparently  
211 enhanced functionality, prompted us to reexamine the growth characteristics of the 44 leucine-  
212 and alanine-scanning mutant alleles using the more nuanced growth-based assays. Serial  
213 dilutions of cell suspensions from strain JKY2 (*shr3Δ*) carrying vector control (VC), *SHR3* or  
214 one of the individual mutant alleles were spotted on SAD + D-histidine, SD + L-canavanine,  
215 SD + AzC and YPD+MM (Supplementary Material Fig. S1-S10). The growth characteristics  
216 were evaluated and the results, including the internal loop deletions, are summarized in an  
217 ordered heat-map (Fig. 3A). As was found in the initial evaluation of growth on YPD+MM,  
218 most of the mutant alleles were judged to encode functional proteins; the strains grew similarly  
219 as the strain carrying the *SHR3* wildtype control. Reevaluation of the three non-functional  
220 alleles, *shr3-35*, *shr3-50* and *shr3-76*, confirmed that the mutations exhibit major defects on all  
221 of the selective media (Fig. 3A). However, in some instances, several of the mutations, similar  
222 to *SHR3Δ94*, conferred robust growth on YPD+MM but did not complement *shr3Δ* on the other  
223 selective media. Strikingly, *SHR3-45*, *-63*, *-65*, *-68*, *-71*, *-74*, and *-75*, supported more robust  
224 growth on YPD + MM than *SHR3*, but exhibited a null phenotype on media containing toxic  
225 amino acid analogues. In summary, growth in the presence of D-histidine was found to be the  
226 most sensitive monitor of mutations in *SHR3*, perhaps due to the fact that D-amino acids are  
227 taken up by a single AAP, Gap1 (Grenson et al., 1970; Rytka, 1975). We note that mutations  
228 localized to the MS III and IV and the ER luminal oriented loop L3 exhibited the most  
229 pleiotropic affects, suggesting that these regions of Shr3 facilitate interactions with discrete  
230 AAP, and potentially, comprise substrate specific determinants.

231 We performed multiple sequence alignments of the membrane domain of Shr3 and orthologs  
232 from two *Saccharomyces sensu stricto* strains, *S. paradoxus* and *S. mikatae*, and from three  
233 divergent *lato* fungal strains, *Candida albicans* (*Csh3*), *Schizosaccharomyces pombe* (*Psh3*)  
234 and *Aspergillus nidulans* (*ShrA*) and obtained a consensus identity plot (Fig. 3B) (Madeira et  
235 al., 2019). The Shr3 orthologs of *C. albicans*, *S. pombe* and *A. nidulans* have been shown to  
236 function analogously and are required for proper amino acid uptake. Heterologous expression  
237 of *CSH3* complements *shr3Δ* (Martínez and Ljungdahl, 2004), whereas heterologous  
238 expression of *PSH3* or *SHRA* only partially complement *shr3Δ*, merely facilitating the  
239 functional expression of limited subset of permeases (Erpapazoglou et al., 2006; Martínez and  
240 Ljungdahl, 2000). The Shr3 sequence is well-conserved in the *Saccharomyces sensu stricto*  
241 strains, exhibiting almost absolute identity. Several positions throughout the membrane domain  
242 of Shr3 are conserved between the full set of selected sequences. Interestingly, threonine 19,  
243 which is the single critical amino acid residue in MS I, is conserved in all orthologs (Fig. 3B,  
244 T19 is highlighted in dark blue). The requirement for a polar amino acid in MS IV of Shr3 is  
245 conserved as well (Fig. 3B, S139 highlighted in dark blue). A higher sequence divergence is  
246 evident in the luminal loop L3, with the extreme case of the *A. nidulans* orthologue that contains  
247 an extra sequence of twelve amino acid residues. The limited sequence identity in loop L3

248 aligns with the observation that mutations in L3 of Shr3 exhibit the most pleiotropic effects,  
249 and is consistent with the notion that L3 affects substrate specificity.

250 The finding that the Shr3 $\Delta$ 94 mutation supported robust growth on YPD+MM, suggested  
251 that the mutant protein retained the capacity to facilitate Ssy1 folding. In contrast to the other  
252 members of the AAP transporter family, Ssy1 functions as the primary receptor of extracellular  
253 amino acids in the context of the plasma membrane-localized SPS sensor (Didion et al., 1998;  
254 Iraqui et al., 1999; Klasson et al., 1999). In response to extracellular amino acids, Ssy1 initiates  
255 signaling events leading to the proteolytic activation of Stp1, which in turn induces the  
256 expression of several AAP genes including *AGPI* and *GNPI* and multiple permeases  
257 facilitating branched amino acid uptake. As an indirect measure of Shr3-Ssy1 interactions, we  
258 examined the proteolytic cleavage of the transcription factor Stp1 (Fig. 3C). Consistent with  
259 the growth assays, leucine induction led to Stp1 processing in strain FGY135 (*shr3* $\Delta$ )  
260 expressing *SHR3* or *SHR3* $\Delta$ 94 (Fig. 3C, lanes 4 and 8), but not the non-functional alleles *shr3*-  
261 35, *shr3*-50 or *shr3*-76 (Fig. 3C, lanes 6, 10 and 12).

262

### 263 **Shr3-AAP substrate interactions**

264 To test if the observed growth phenotypes of the mutated *SHR3/shr3* alleles correlated with the  
265 ability of mutant Shr3/*shr3* proteins to interact with specific AAP and facilitate their functional  
266 expression we exploited a split-ubiquitin approach to monitor Shr3-AAP interactions *in vivo*  
267 (Fig. 4A and 4B). A sequence encoding the N-terminal fragment of ubiquitin carrying the I13A  
268 mutation (NubA), which reduces the propensity of non-specific interactions (Johnsson, 2002;  
269 Johnsson and Varshavsky, 1994), was fused at the C-terminal end of *SHR3*, *shr3*-35, and  
270 *SHR3* $\Delta$ 94, creating the Shr3-NubA constructs schematically depicted in Fig. 4A. Next, we  
271 created a *GAPI* allele encoding the C-terminal fragment of ubiquitin (Cub) tagged with GST-  
272 6xHA (Cub-GST) (Fig. 4A). The resulting *GAPI*-Cub-GST was placed under the control of the  
273 *GALI*-promoter. When co-expressed, productive interactions between Gap1 and Shr3 enable  
274 the split NubA and Cub domains to assemble a functional ubiquitin moiety that is recognized  
275 by ubiquitin-specific proteases, resulting in the release of the GST-6xHA reporter (Fig. 4B).  
276 The functional attributes of the NubA fusion constructs were tested by their ability to  
277 complement *shr3* $\Delta$  (Fig. 4C, dilutions 3-5); strains carrying *SHR3*-NubA or *SHR3* $\Delta$ 94-NubA  
278 grew as well as *SHR3* without NubA (Fig. 4C, compare dilution 2 with 3 and 5), whereas the  
279 *shr3*-35-NubA allele did not (dilution 4). The *GAPI*-Cub-GST allele encodes a functional Gap1  
280 protein that facilitates citrulline uptake as well as wildtype Gap1 (Fig. 4C, compare dilution 7  
281 with 8). The functionality of Gap1-Cub-GST is dependent on its ability to exit the ER; a  
282 construct lacking the ER exit motif in the hydrophilic C-terminal domain of Gap1 is not  
283 functional (Fig. 4C dilution 9), presumably due its retention in the ER.



284 To test *in vivo* interactions, we analyzed protein extracts from strain FGY135 (*shr3Δ gap1Δ*)  
285 carrying plasmids *GAP1-Cub-GST* and *SHR3-NubA*, *shr3-35-NubA* or *SHR3Δ94-NubA* using  
286 anti-HA immunoblot analysis. In cells expressing *SHR3-NubA* or *SHR3Δ94-NubA* and *GAP1-*  
287 *Cub-GST-6xHA*, two bands were detected, corresponding to full-length Gap1-Cub-GST-6xHA  
288 and the cleaved GST-6xHA (Fig. 4D, lane 1). We calculated the fraction of split-ubiquitin  
289 cleavage in the *SHR3-NubA* strain to be  $\approx 20\%$  by dividing the intensities of the cleaved band  
290 with the intensities from full-length plus cleaved species; whereas in the *SHR3Δ94-NubA* strain  
291 the cleavage was 5% (Fig. 4D); By contrast, only a single band, full-length Gap1-Cub-GST-  
292 6xHA, was detected in extracts from the strain expressing the non-functional *shr3-35-NubA*  
293 and *GAP1-Cub-GST-6xHA* constructs (Fig. 4D, lane 2). Although expressed at similar levels,  
294 the ER retained gap1-ERX<sub>AAA</sub>-Cub-GST protein did not exhibit an enhanced propensity to  
295 interact with Shr3, suggesting the split-ubiquitin assay primarily monitors transient interactions  
296 during AAP biogenesis (Fig. S11).

297 Based on the success of the split ubiquitin approach to analyze Shr3-Gap1 interactions, we  
298 created Cub-GST-6xHA tagged constructs with five additional AAP, i.e., Agp1, Gnp1, Bap2,  
299 Can1 and Lyp1, the non-transporting but Shr3-dependent AAP homologue Ssy1 (Klasson *et*  
300 *al.*, 1999), and two Shr3-independent sugar transporters (HXT), i.e., the low-affinity glucose  
301 transporter Hxt1 and the galactose transporter Gal2 (Fig. 5A). Extracts from strain FGY135  
302 (*shr3Δ gap1Δ*) carrying *SHR3-NubA*, *shr3-35-NubA* or *SHR3Δ94-NubA* and a single *AAP-Cub-*  
303 *GST-6xHA* or *HXT-Cub-GST-6xHA* construct were prepared and the levels of the GST-6xHA  
304 reporter were determined (Fig. 5B-E). Consistent with the general requirement of Shr3 for AAP  
305 folding, robust interactions were detected between Agp1-, Gnp1-, Bap2- and Ssy1-Cub  
306 constructs and wildtype Shr3-NubA (Fig. 5B, C). Although Shr3 is required for their functional  
307 expression, Can1- and Lyp1-Cub constructs exhibited low levels of reporter cleavage, similar  
308 to the Shr3-independent sugar transporters (Fig. 5D, E). These latter observations are consistent  
309 with Shr3 functioning in a transient manner, primarily interacting with AAP substrates during  
310 early stages of AAP folding. In the context of full-length AAP, the split-ubiquitin signal may  
311 reflect weaker post-folding interactions.

312 AAP-Cub interactions with *shr3-35-NubA* were weak or absent, which is precisely aligned  
313 with it being non-functional on all selective media tested (Fig. 1, 3). Unexpectedly, the split-  
314 Ub interactions with unrelated sugar transporters (HXT) were also weaker compared to the  
315 wildtype Shr3-NubA (Fig. 5E). This prompted us to test the trivial explanation that the NubA  
316 domain of Shr3-35-NubA is incorrectly oriented. The NubA is correctly oriented to the  
317 cytoplasm and thus in a context capable of supporting potential interactions (Supplementary  
318 Material, Fig. 12A). Together these findings indicate that the *shr3-35* protein, although  
319 expressed at similar levels as Shr3, is incapable of engaging in both specific and non-specific  
320 secretory substrate interactions.

321 Interestingly, the Shr3 $\Delta$ 94-NubA interacted with all AAP-Cub constructs, but at  
322 significantly reduced levels, and consequently, the data did not explain the enhanced growth  
323 conferred by the *SHR3 $\Delta$ 94* allele on YPD + MM (Fig. 2 and 3). In marked contrast, Shr3 $\Delta$ 94-  
324 NubA interacted with Ssy1-Cub-GST-6xHA at levels comparable to Shr3-NubA (Fig.5 C),  
325 which provided the mechanistic explanation for the enhanced growth phenotype. Ssy1 is a  
326 unique member of the AAP family that strictly requires Shr3 for folding (Klasson *et al.*, 1999)  
327 and constitutes the integral membrane component of the PM-localized SPS sensor that induces  
328 the expression of AAP genes in response to extracellular amino acids (Ljungdahl and Daignan-  
329 Fournier, 2012). Apparently, the Shr3 $\Delta$ 94 mutant retains ability to assist the folding of Ssy1,  
330 restoring the transcriptional circuits abrogated by *shr3 $\Delta$* . Consistent with this notion, the  
331 Shr3 $\Delta$ 94 allele supports Stp1 processing (Fig. 3C). The induced expression of multiple AAP  
332 that facilitate branched-chain amino acid uptake correlates well with the growth-based  
333 phenotypes. Together, the results indicate that the *in vivo* interactions monitored by the split  
334 ubiquitin cleavage provide a nuanced assessment of Shr3 function.

335

### 336 **Shr3 interacts with substrates in a progressive manner**

337 As a proxy to investigate the temporal aspects of Shr3-facilitated AAP folding, we constructed  
338 a series of truncated *gap1-Cub-GST*, *hxt1-Cub-GST* and *gal2-Cub-GST* alleles capable of  
339 encoding 2, 4, 6, 8, 10 and 12 MS (Fig. 6A). Strain FGY135 (*shr3 $\Delta$  gap1 $\Delta$* ) carrying plasmid  
340 *SHR3-NubA* and a truncated *gap1-Cub-GST*, *hxt1-Cub-GST* or *gal2-Cub-GST* allele was  
341 employed and potential interactions were monitored by immunoblot. Shr3-NubA did not  
342 interact with *gap1-2TM*, even though the Cub domain is presented in the context of proper  
343 membrane topology oriented towards the cytoplasm (Supplementary Material, Fig. S12 B). The  
344 presence of two additional MS of Gap1 (*gap1-4TM*) supported an interaction with Shr3 (Fig. 6  
345 B left panel, C in black). The intensity of the interactions increased and eventually plateaued in  
346 the strains carrying the *gap1-6TM/-8TM/-10TM* alleles, respectively (Fig. 6 B left panel, C in  
347 black). Strikingly, the *gap1-12TM* construct interacted only weakly with the functional Shr3-  
348 NubA (Fig. 6 B left panel, C in black). In marked contrast to the interaction pattern of the *gap1-  
349 Cub-GST* truncations with Shr3-NubA, we could not detect the GST-6xHA reporter in extracts  
350 from the strain expressing *SHR3-NubA* and any of the truncated *hxt1-Cub-GST* or *gal2-Cub-  
351 GST* alleles (Fig. 6B, center and left panel, C in grey and white). These findings support the  
352 notion that our split ubiquitin approach is suitable to monitor specific Shr3-AAP interactions.  
353 As a critical test, we examined if robust interactions could be detected between Shr3-NubA and  
354 two truncated Can1 constructs with eight and ten MS (Fig. S13). The rationale being that growth-  
355 based and biochemical assays have clearly defined Can1 as a *bona fide* substrate of Shr3.  
356 However, interactions between full-length Can1 and Shr3 are weak, similar to that  
357 corresponding to the non-Shr3 substrates Hxt1 and Gal2 (Fig. 5D and E). We posited that if

358 truncations of AAP are indeed proxies of translation intermediates, then truncations of Can1  
359 would readily interact with Shr3. Interactions between the can1-8TM and -10TM Cub  
360 constructs with Shr3-NubA were readily detected (Fig. S13 B, C), findings clearly consistent  
361 with Shr3 functioning at early stages of AAP biogenesis.

362 To more fully understand Shr3-substrate interactions, we created a series of truncated Agp1  
363 and Ssy1 split-ubiquitin constructs (Fig. 7A). Interestingly, in contrast to gap1-2TM, the agp1-  
364 2TM construct clearly interacted with Shr3-NubA (Fig. 7A; black bars). Aside from this  
365 difference, the pattern of interactions with the remaining Agp1 constructs was strikingly similar  
366 to that observed with Gap1 truncations; the intensity of the GST-6xHA reporter increased  
367 successively as the number of MS increased from 4 to 10, and greatly reduced when all 12 TM  
368 were present (Fig. 7A, black bars). The interactions of the Shr3 $\Delta$ 94-NubA with the agp1-Cub  
369 constructs followed a similar pattern to that of the wildtype Shr3-NubA, albeit of lower intensity  
370 (Fig. 7A, white bars). Notedly, the interaction pattern with the Ssy1 constructs was quite  
371 different (Fig. 7B). Interestingly, as did agp1-2TM, the ssy1-2TM interacted with Shr3-NubA,  
372 strongly suggesting that Shr3 engages early during the biogenesis of Ssy1. The ssy1-4TM and  
373 -6TM constructs exhibited weaker interactions, however, the ssy1-8TM, -10TM and -12TM  
374 constructs exhibited robust interactions. As anticipated from growth-based assays, Shr3 $\Delta$ 94-  
375 NubA exhibited an interaction pattern very similar to the wildtype Shr3-NubA construct.

376

## 377 Discussion

378 The biogenesis of AAP can be divided into three interconnected but discrete functional steps:  
379 1) co-translational partitioning and integration into the ER membrane; 2) folding into native  
380 structures; and 3) packaging into ER-derived COPII-coated transport vesicles. Shr3 is not  
381 essential for integration (Gilstring and Ljungdahl, 2000), but is required for folding and  
382 packaging into COPII-coated vesicles (Gilstring *et al.*, 1999; Kuehn *et al.*, 1998; Kuehn *et al.*,  
383 1996); Kota and Ljungdahl, 2005;(Kota *et al.*, 2007; Kota and Ljungdahl, 2005). Here, our  
384 studies were aimed at further elucidating the role of Shr3 in facilitating AAP folding, i.e. its  
385 membrane-localized chaperone (MLC) function.

386 Saturation scanning mutagenesis of the N-terminal membrane domain of Shr3 allowed us  
387 to define amino acid residues that are critical for the recognition of AAP as folding substrates  
388 (Supplementary Material Fig. S1-S10; Fig. 3A). Strikingly, mutations affecting a few amino  
389 acids residues at three discrete sites resulted in a complete loss of function, suggesting that Shr3  
390 generally recognizes its folding substrates independently of sequence-specific interactions, but  
391 rather based on the presence of structural determinants shared by the AAP. The critical residues  
392 identified in MSI and MSIV shared the common feature of being polar (Fig. 1C). Threonine19  
393 is conserved among closely and more distant fungal species (Fig. 3B), and it is of interest to  
394 note that one of the original spontaneous mutations that led to the identification of *SHR3* is a

395 T19R mutation (Ljungdahl *et al.*, 1992). Strikingly, two mutant proteins carrying 10  
396 consecutive leucine residues (aa 62-71, Shr3-57, MSII) or 9 (aa 145-153, Shr3-79, MSIV)  
397 support functional expression of AAP in manner indistinguishable from wildtype Shr3, and the  
398 Shr3-58 mutant with 13 consecutive leucine residues (aa 69-81, MSII) functions well for all  
399 AAP except Gap1 (Fig. 3A, Fig. S6). These findings suggest that hydrophobic interactions  
400 between MS of Shr3 and AAP can develop even at the expense of larger sections of specific  
401 Shr3 sequence, presumably provided that its overall membrane structure is retained. The data  
402 are consistent with Shr3 acting as a scaffold for AAP folding, a function that primarily depends  
403 on hydrophobic interactions but with the capacity to shield energetically unfavorable polar  
404 residues of AAP MS. Importantly, exposed polar residues may be recognized by a hydrophilic  
405 pocket identified in the structure of the ERAD-associated E3 ubiquitin ligase Hrd1 (Schoebel  
406 *et al.*, 2017), which participates in the degradation of misfolded AAP in cells lacking Shr3 (Kota  
407 *et al.*, 2007).

408 The finding that one of the three loss-of-function mutations disrupting Shr3 function  
409 resides in the lumen-oriented loop L1 (Fig. 1) suggests that the role of Shr3 as a MLC is not  
410 restricted to MS-mediated hydrophobic interactions. Apparently, Shr3 facilitates the folding of  
411 AAP in a manner dependent on extramembrane lumen-oriented sequences. Consistent with this,  
412 all internal deletions in L1 of Shr3 strongly affected its function (Fig. 2). Interestingly, L1  
413 contains a predicted  $\alpha$ -helical structure with amphipathic characteristics (aa 44-57) that is  
414 disrupted in each of the internal deletion mutant proteins.

415 By contrast to mutations affecting L1, the deletion affecting L3 (*SHR3* $\Delta$ 94) exhibited a  
416 variable effect on amino acid uptake (Fig. 2), a phenotype that we could trace to differential  
417 interactions with distinct AAP substrates. Consequently, the data implicate L3 as an important  
418 determinant that influences substrate interactions. This region appears to be critical for  
419 interactions with Gap1 and Can1, but less important for interactions with Agp1/Gnp1, and  
420 clearly dispensable for interactions with Ssy1 (Fig. 2, Fig. 4, Fig. 5). Consistently, some  
421 mutations in *SHR3* result in WT<sup>+</sup> phenotypes, i.e., exhibiting more robust growth than wildtype  
422 (Fig. 3A). This latter gain-of-function phenotype is presumably due to proper Ssy1 folding;  
423 cells that carry these mutations remain capable of inducing AAP gene expression in a manner  
424 that is augmented by the derepression of nitrogen regulation (Ljungdahl and Daignan-Fornier,  
425 2012). Thus, under the specific growth conditions used, cells carrying L3 mutations express  
426 enhanced levels of AAP leading to WT<sup>+</sup> growth phenotype.

427 The observation that Ssy1, the only non-transporting AAP, exhibits a lax requirement for  
428 L3 to fold, suggests that transporting AAP may have an enhanced requirement for the chaperone  
429 function of Shr3. This notion is consistent with recent evidence showing that extracellular loops  
430 of AAP are not merely MS-connecting sequences but rather have important roles affecting  
431 intracellular trafficking and transport function (van't Klooster *et al.*, 2020). Some of the

432 hydrophilic loops of AAP are of considerable length, especially extracellular loops 3 and 4  
433 connecting MS V-VI and VII-VIII, respectively. Secondary structure predictions suggest the  
434 extracellular loop 4 of the lysine permease Lyp1 (van't Klooster *et al.*, 2020) and Gap1  
435 (Ghaddar *et al.*, 2014a) possesses  $\alpha$ -helical regions that appear to influence the substrate  
436 specificity of amino acid transport (Risinger *et al.*, 2006). Consistent with a requirement for the  
437 lumen-oriented loops of Shr3, the loop regions of AAP that face the extracellular milieu are  
438 lumen-oriented during biogenesis. Interactions between the lumen-oriented loops of Shr3 may  
439 prevent precocious folding of the extracellular loops, maintaining them in a more flexible state  
440 required for subsequent folding events, e.g., involving MS that fold in a context with more  
441 distal C-terminal MS. In analogy, proper trafficking and functional expression of the closest  
442 AAP homologues in mammals, the L-type amino acid transporters (LAT) (SLC7 family)  
443 depend on extramembrane region-mediated recognition by the 4F2hc, or rBAT, members of  
444 the SLC3 protein family (Fotiadis *et al.*, 2013). The extracellular orientation of the interacting  
445 regions upon plasma-membrane localization of the SLC7-SLC3 holo-LAT transporters is in  
446 line with the concept of extramembrane regions containing motifs for substrate recognition and  
447 specificity exhibited by amino acid transporter biogenesis factors (Rosell *et al.*, 2014).

448 Although there is no crystal structure of an AAP, Bap2 (Usami *et al.*, 2014), Can1 (Ghaddar  
449 *et al.*, 2014a), Gap1 (Ghaddar *et al.*, 2014b) and Tat2 (Kanda and Abe, 2013) have been  
450 successfully modeled onto the *E. coli* arginine/agmatine antiporter AdiC (Gao *et al.*, 2010).  
451 AdiC has 12 MS and belongs to the Amino Acid-Polyamine-Organocation (APC) super-family  
452 of transporters. The 12 MS are arranged in a 5+5 inverted repeat fold that form the transporter  
453 core, with MS XI and XII appearing to hold the two halves together. MS I, III, VI, VIII and X  
454 shape the binding pocket. To directly probe the *in vivo* interactions between Shr3 and AAP we  
455 adapted and applied a split-ubiquitin approach that is independent of a transcriptional readout.

456 In the context of full-length AAP, we found that the split-ubiquitin signal was relatively  
457 weak, specifically in comparison to the signals with truncated substrates. Also, we detected  
458 low levels of interactions with full length non-Shr3 substrates that do not rely on Shr3  
459 chaperone function for folding, indicating that the split-ubiquitin approach is sensitive and  
460 accurately reflects biologically relevant interactions. Perhaps, Shr3 can interact with many  
461 secretory substrates but some interactions become stronger and specific when structural  
462 characteristics distinct from the general ones are involved. In support of this notion, the pattern  
463 of interactions between Shr3 and truncated Gap1, Agp1, Can1 and Ssy1 is striking, particularly  
464 in contrast to truncated HXT (Hxt1 and Gal2) exhibiting essentially no interactions (Fig. 6, 7,  
465 and S13). The specific interactions with AAP were detected when only the first 2 to 4 MS were  
466 present. As more MS were added the interactions increased and plateaued until MS XI and XII  
467 were present, at which point the interactions significantly lessen. By contrast, full-length (Fig.  
468 5) and 12MS truncated (Fig. 7) forms of Ssy1 exhibited more persistent interactions with Shr3  
469 and Shr3 $\Delta$ 94, perhaps attributable to Ssy1 being substantially larger than transporting AAP.

470 Together, the data we acquired in this study provide further support to our previously  
471 described model (Kota *et al.*, 2007; Kota and Ljungdahl, 2005) whereby Shr3 transiently  
472 interacts with AAP early as their MS partition into the ER membrane, acting as an assembly  
473 site for MS helices. This activity is required to prevent AAP translation intermediates from  
474 engaging in nonproductive interactions, shielding polar residues, until all MS are available and  
475 presented in a context of the long-range intramolecular interactions inherent to the native 3D-  
476 structure of AAP (Fig.8). Our model for the Shr3 chaperone function in the biogenesis of AAP  
477 is analogous to that of the bacterial insertase/chaperone YidC (Beck *et al.*, 2001; (Dalbey and  
478 Kuhn, 2014) acting as an assembly site for alpha helices in the folding of LacY whereby  
479 hydrophobic interactions mediate shielding of LacY to provide a protective chamber that  
480 reduces energetically unfavorable contacts in the non-native structure during translation  
481 (Nagamori *et al.*, 2004; Serdiuk *et al.*, 2016; Serdiuk *et al.*, 2019; Wagner *et al.*, 2008; Zhu *et al.*,  
482 2013). Similar transient MLC-substrate interactions have been reported in the case of the  
483 mammalian PAT intramembrane chaperone complex, comprised of four MS, three contributed  
484 by Asterix and one by CCDC47 (Chitwood and Hegde, 2020). Although in these studies an *in*  
485 *vitro* translation system was employed, in contrast to our *in vivo* split-ubiquitin approach, the  
486 PAT complex interaction was found to be selective for truncated, immature  $\beta$ 1-adrenergic  
487 receptor constructs compared to the full-length substrate, which presumably is capable of helix  
488 packing and polar residue shielding.

489 The chaperone-like capacity of the conserved eukaryotic ER membrane protein complex  
490 (EMC) insertase has recently been explored (Bai *et al.*, 2020; O'Donnell *et al.*, 2020; Pleiner *et al.*,  
491 2020; Volkmar and Christianson, 2020). The results point to EMC acting in close proximity  
492 with nascent polytopic membrane proteins typically enriched for MS containing polar or  
493 charged residues, shielding them from degradation during folding (Miller-Vedam *et al.*, 2020;  
494 Shurtleff *et al.*, 2018). Importantly, the EMC can associate with a number of ER-integral  
495 substrate-specific chaperones such as Sop4 (Luo *et al.*, 2002), Gsf2 (Kota and Ljungdahl, 2005;  
496 Sherwood and Carlson, 1999) and Ilm1 (Shurtleff *et al.*, 2018). Shr3, although an abundant ER  
497 membrane protein, has not been identified as an interacting partner of EMC components  
498 (Shurtleff *et al.*, 2018). Potentially, Shr3 and the EMC act in proximity to distinct ribosome  
499 populations, functioning in a parallel manner, enabling the Sec61 translocon to pair with diverse  
500 and distinct sets of partners, and thereby facilitate the efficient biogenesis of more challenging  
501 versus canonical substrates of the secretory pathway (O'Keefe and High, 2020).

502 In the case of Shr3, the early interactions with nascent AAP being inserted in the lipid  
503 bilayer together with the ability of Shr3 to interact with COPII components via its C-terminal  
504 cytoplasmic tail (Gilstring *et al.*, 1999), converge to function as a nexus between AAP folding  
505 and packaging into COPII-coated vesicles. The potential network of dynamic interactions in  
506 the ER remains to be explored for an integral substrate-specific chaperone as well as what  
507 structural determinants in the substrates dictate a remarkable degree of substrate specificity. To

508 this end, the broad collection of mutations that we have acquired in combination to our extended  
509 growth-based phenotype analysis and in vivo interaction studies lay the ground for future  
510 structural studies that are required to gain insights into the mechanistic details that underlie this  
511 substrate-specific MLC function.

512

## 513 **Materials and methods**

### 514 **Yeast strains and plasmids**

515 Yeast strains and plasmid used are listed in Supplementary Material Tables S1 and S2,  
516 respectively.

517

### 518 **Media**

519 Standard media, YPD (yeast extract, peptone, dextrose), SD (synthetic defined with ammonium  
520 as nitrogen source and glucose as carbon source) were prepared as previously described (Burke  
521 et al., 2000). Ammonia-based synthetic complete dextrose (SC) drop-out medium, were  
522 prepared as described (Andréasson and Ljungdahl, 2002) and SAD (synthetic minimal  
523 dextrose, with allantoin as sole nitrogen source) was prepared as previously described. Media  
524 were made solid with 2% (wt/vol) bacto Agar (Difco), 2% (wt/vol) washed bacto Agar (Difco)  
525 or 2% (wt/vol) washed pure Agar where indicated. Sensitivity to 200 µg/ml MM (2- $\{[(4-$   
526 methoxy-6-methyl)-1,3,5-triazin-2-yl]-amino}carbonyl amino]-sulfonyl}-benzoic acid) was  
527 tested on YPD as described previously (Jørgensen *et al.*, 1998). Sensitivity to 1 mM AzC  
528 (azetidine-2-carboxylate), 10 µg/ml DL-ethionine, 50 µg/ml p-Fluoro-DL-phenylalanine and 1  
529 µg/ml L-canavanine was tested on SD. Sensitivity to 0,5% (wt/vol) D-histidine was tested on  
530 SAD media made solid with washed pure Agar. Cells were grown over night in SC-uracil  
531 medium, cells were then resuspended in water to OD=1, 10-fold dilutions were prepared in  
532 water and then spotted on the indicated medium. Plates were then incubated at 30°C for 2–3 d  
533 and photographed. Gap1-dependent citrulline uptake was monitored on minimal medium  
534 containing 2 % galactose as carbon source, 1 mM L-citrulline as sole nitrogen source and uracil.  
535 Media were made solid with washed bacto Agar. Plates were incubated at 30 °C for 7 d and  
536 photographed.

537

### 538 **Immunoblot analysis**

539 Whole-cell extracts were prepared under denaturing conditions using NaOH and trichloroacetic  
540 acid as described previously (Silve et al., 1991). Proteins were separated using SDS-PAGE and  
541 blotted onto Amersham Protran 0.45 µm nitrocellulose membrane (GE Healthcare). The  
542 primary antibodies and dilutions were, mouse anti-Dpm1 5C5A7 (Abcam), 1:2500; rat anti-

543 HA-HRP 3F10 (Roche Applied Science), 1:2500-1:5000; mouse anti-Pgk1 22C5D8 (Thermo  
544 Fisher Scientific), 1:10000 and rabbit anti-Shr3, 1:9000. Secondary antibodies and dilutions  
545 used were, goat anti-mouse-poly-HRP (Thermo Fisher Scientific), 1:5000 and goat anti-rabbit-  
546 poly-HRP (Thermo Fisher Scientific), 1:5000. Immunoreactive bands were visualized by  
547 chemiluminescence using (SuperSignal West Dura Extended-Duration Substrate; Thermo  
548 Fisher Scientific) as substrate in a ChemiDoc imaging system (Biorad).

549

### 550 **Split-ubiquitin assay**

551 Cells were pre-grown in SD+R (synthetic defined with ammonium as nitrogen source and 2 %  
552 raffinose and 0.1 % glucose as carbon source) to logarithmic phase. Approximately 10 OD of  
553 logarithmically cells were induced in 5 ml of SD+G (synthetic defined with ammonium as  
554 nitrogen source and 2 % galactose as carbon source) for 1 hour. Cells were collected and washed  
555 once in ddH<sub>2</sub>O. Cells were resuspended in 150 µl lysis buffer (0.8 M sorbitol; 10 mM MOPS,  
556 pH 7.2; 2 mM EDTA; 1 mM PMSF; 1X cOmplete, mini, EDTA-free protease inhibitor cocktail,  
557 Roche). Cells were lysed by bead beating with 0.5 mm glass beads for 3x20s at 6.5 m/s in a  
558 benchtop homogenizer (Fastprep-24, MP Biomedical). The cell lysates were centrifuged at  
559 500g for 10 min and 25 µl of the resulting supernatant was diluted 1:1 with 2x sample buffer.  
560 Proteins were separated using SDS-PAGE and blotted onto Amersham Protran 0.45 µm  
561 nitrocellulose membrane (GE Healthcare). The primary antibody and dilution used was rat anti-  
562 HA-HRP 3F10 (Roche Applied Science), 1:2500-1:5000. Immunoreactive bands were  
563 visualized by chemiluminescence using (SuperSignal West Dura Extended-Duration Substrate;  
564 Thermo Fisher Scientific) as substrate in a ChemiDoc imaging system (Biorad).

565

### 566 **Protease protection assay**

567 Cells were pre-grown in SD+R (synthetic defined with ammonium as nitrogen source and 2 %  
568 raffinose and 0.1 % glucose as carbon source) to logarithmic phase. Approximately 5 OD of  
569 logarithmically cells were induced in 5 ml of SD+G (synthetic defined with ammonium as  
570 nitrogen source and 2 % galactose as carbon source) for 1 hour. Cells were collected and washed  
571 once in ddH<sub>2</sub>O. Cells were resuspended in 150 µl lysis buffer (0.8 M sorbitol; 10 mM MOPS,  
572 pH 7.2; 2 mM EDTA; 1 mM PMSF; 1X cOmplete, mini, EDTA-free protease inhibitor cocktail,  
573 Roche). Cells were lysed by bead beating with 0.5 mm glass beads for 3x20s at 6.5 m/s in a  
574 benchtop homogenizer (Fastprep-24, MP Biomedical). The cell lysates were centrifuged at  
575 500g for 10 min and 100 µl of the resulting supernatant was centrifuged at 100 000 g for 30  
576 minutes. The membrane pellet was resuspended in 50 µl lysis buffer (0.8 M sorbitol; 10 mM  
577 MOPS, pH 7.2; 2 mM EDTA; 5 mM CaCl<sub>2</sub>). The resulting membrane preparations were  
578 digested with 20 µg Proteinase K (Thermo Fisher Scientific) on ice with 0.2 % NP-40 as



579 indicated. Time points were taken at 0 and 2 h. Proteins were precipitated using trichloroacetic  
580 acid as described previously (Silve *et al.*, 1991). Proteins were separated using SDS-PAGE and  
581 blotted onto Amersham Protran 0.45  $\mu$ m nitrocellulose membrane (GE Healthcare). The  
582 primary antibodies and dilutions used were, rat anti-HA-HRP 3F10 (Roche Applied Science),  
583 1:2500-1:5000 and rabbit anti-Kar2, 1:5000. Secondary antibody and dilution used was goat  
584 anti-rabbit-poly-HRP (Thermo Fisher Scientific), 1:5000. Immunoreactive bands were  
585 visualized by chemiluminescence using (SuperSignal West Dura Extended-Duration Substrate;  
586 Thermo Fisher Scientific) as substrate in a ChemiDoc imaging system (Biorad).

587

## 588 **Acknowledgements**

589 We thank the members of the Ljungdahl laboratory and Claes Andréasson for constructive  
590 comments throughout the course of this work. In particular we acknowledge Nina Horwege,  
591 and Carlos Sacristán for early contributions in creating plasmid constructs. This research was  
592 supported by funding from Swedish Research Council (P.O.L.), Grant/Award numbers: 2011-  
593 5925 and 2015-04202.

594

## 595 **Competing interests**

596 The authors have no conflicts of interest to report.

597

## 598 **References**

- 599 Andréasson, C., and Ljungdahl, P.O. (2002). Receptor-mediated endoproteolytic activation  
600 of two transcription factors in yeast. *Genes Dev.* *16*, 3158-3172.
- 601 Andréasson, C., Neve, E.P.A., and Ljungdahl, P.O. (2004). Four permeases import proline  
602 and the toxic proline analogue azetidine-2-carboxylate into yeast. *Yeast* *21*, 193-199.
- 603 Bai, L., You, Q., Feng, X., Kovach, A., and Li, H. (2020). Structure of the ER membrane  
604 complex, a transmembrane-domain insertase. *Nature* *584*, 475-478. 10.1038/s41586-  
605 020-2389-3.
- 606 Chitwood, P.J., and Hegde, R.S. (2020). An intramembrane chaperone complex facilitates  
607 membrane protein biogenesis. *Nature* *584*, 630-634. 10.1038/s41586-020-2624-y.
- 608 Dalbey, R.E., and Kuhn, A. (2014). How YidC inserts and folds proteins across a membrane.  
609 *Nat Struct Mol Biol* *21*, 435-436. 10.1038/nsmb.2823.
- 610 Didion, T., Regenberg, B., Jørgensen, M.U., Kielland-Brandt, M.C., and Andersen, H.A.  
611 (1998). The permease homologue Ssy1p controls the expression of amino acid and  
612 peptide transporter genes in *Saccharomyces cerevisiae*. *Mol. Microbiol.* *27*, 643-650.
- 613 Drozdetskiy, A., Cole, C., Procter, J., and Barton, G.J. (2015). JPred4: a protein secondary  
614 structure prediction server. *Nucleic Acids Res* *43*, W389-394. 10.1093/nar/gkv332.


- 615 Erpapazoglou, Z., Kafasla, P., and Sophianopoulou, V. (2006). The product of the SHR3  
616 orthologue of *Aspergillus nidulans* has restricted range of amino acid transporter targets.  
617 *Fungal Genet Biol* 43, 222-233. 10.1016/j.fgb.2005.11.006.
- 618 Fotiadis, D., Kanai, Y., and Palacin, M. (2013). The SLC3 and SLC7 families of amino acid  
619 transporters. *Mol Aspects Med* 34, 139-158. 10.1016/j.mam.2012.10.007.
- 620 Gao, X., Zhou, L., Jiao, X., Lu, F., Yan, C., Zeng, X., Wang, J., and Shi, Y. (2010). Mechanism of  
621 substrate recognition and transport by an amino acid antiporter. *Nature* 463, 828-832.  
622 10.1038/nature08741.
- 623 Ghaddar, K., Krammer, E.M., Mihajlovic, N., Brohee, S., Andre, B., and Prevost, M. (2014a).  
624 Converting the yeast arginine can1 permease to a lysine permease. *J Biol Chem* 289, 7232-  
625 7246. 10.1074/jbc.M113.525915.
- 626 Ghaddar, K., Merhi, A., Saliba, E., Krammer, E.M., Prevost, M., and Andre, B. (2014b).  
627 Substrate-induced ubiquitylation and endocytosis of yeast amino acid permeases. *Mol*  
628 *Cell Biol* 34, 4447-4463. 10.1128/MCB.00699-14.
- 629 Gilstring, C.F., and Ljungdahl, P.O. (2000). A method for determining the in vivo topology  
630 of yeast polytopic membrane proteins demonstrates that Gap1p fully integrates into the  
631 membrane independently of Shr3p. *J. Biol. Chem.* 275, 31488-31495.
- 632 Gilstring, C.F., Melin-Larsson, M., and Ljungdahl, P.O. (1999). Shr3p mediates specific  
633 COPII coatomer-cargo interactions required for the packaging of amino acid permeases  
634 into ER-derived transport vesicles. *Mol. Biol. Cell* 10, 3549-3565.
- 635 Grenson, M., Hou, C., and Crabeel, M. (1970). Multiplicity of the amino acid permeases in  
636 *Saccharomyces cerevisiae*. IV. Evidence for a general amino acid permease. *J Bacteriol*  
637 103, 770-777.
- 638 Gresham, D., Usaite, R., Germann, S.M., Lisby, M., Botstein, D., and Regenber, B. (2010).  
639 Adaptation to diverse nitrogen-limited environments by deletion or extrachromosomal  
640 element formation of the GAP1 locus. *Proc Natl Acad Sci U S A* 107, 18551-18556.  
641 10.1073/pnas.1014023107.
- 642 Heinrich, S.U., Mothes, W., Brunner, J., and Rapoport, T.A. (2000). The Sec61 complex  
643 mediates the integration of a membrane protein by allowing lipid partitioning of the  
644 transmembrane domain. *Cell* 102, 233-244.
- 645 Heinrich, S.U., and Rapoport, T.A. (2003). Cooperation of transmembrane segments  
646 during the integration of a double-spanning protein into the ER membrane. *Embo J* 22,  
647 3654-3663.
- 648 Hou, B., Lin, P.J., and Johnson, A.E. (2012). Membrane protein TM segments are retained  
649 at the translocon during integration until the nascent chain cues FRET-detected release  
650 into bulk lipid. *Mol Cell* 48, 398-408. 10.1016/j.molcel.2012.08.023.
- 651 Iraqui, I., Vissers, S., Bernard, F., de Craene, J.O., Boles, E., Urrestarazu, A., and André, B.  
652 (1999). Amino acid signaling in *Saccharomyces cerevisiae*: a permease-like sensor of  
653 external amino acids and F-Box protein Grr1p are required for transcriptional induction

- 654 of the *AGP1* gene, which encodes a broad-specificity amino acid permease. *Mol. Cell. Biol.*  
655 *19*, 989-1001.
- 656 Jack, D.L., Paulsen, I.T., and Saier, M.H. (2000). The amino acid/polyamine/organocation  
657 (APC) superfamily of transporters specific for amino acids, polyamines and  
658 organocations. *Microbiology 146 ( Pt 8)*, 1797-1814. 10.1099/00221287-146-8-1797.
- 659 Johnson, A.E., and van Waes, M.A. (1999). The translocon: a dynamic gateway at the ER  
660 membrane. *Annu Rev Cell Dev Biol 15*, 799-842. 10.1146/annurev.cellbio.15.1.799.
- 661 Johnsson, N. (2002). A split-ubiquitin-based assay detects the influence of mutations on  
662 the conformational stability of the p53 DNA binding domain in vivo. *FEBS Lett 531*, 259-  
663 264. S0014579302035330 [pii].
- 664 Johnsson, N., and Varshavsky, A. (1994). Split ubiquitin as a sensor of protein interactions  
665 in vivo. *Proc Natl Acad Sci U S A 91*, 10340-10344.
- 666 Jørgensen, M.U., Bruun, M.B., Didion, T., and Kielland-Brandt, M.C. (1998). Mutations in  
667 five loci affecting GAP1-independent uptake of neutral amino acids in yeast. *Yeast 14*, 103-  
668 114.
- 669 Kanda, N., and Abe, F. (2013). Structural and functional implications of the yeast high-  
670 affinity tryptophan permease Tat2. *Biochemistry 52*, 4296-4307. 10.1021/bi4004638.
- 671 Klasson, H., Fink, G.R., and Ljungdahl, P.O. (1999). Ssy1p and Ptr3p are plasma membrane  
672 components of a yeast system that senses extracellular amino acids. *Mol Cell Biol 19*,  
673 5405-5416.
- 674 Kota, J., Gilstring, C.F., and Ljungdahl, P.O. (2007). Membrane chaperone Shr3 assists in  
675 folding amino acid permeases preventing precocious ERAD. *J Cell Biol 176*, 617-628.  
676 10.1083/jcb.200612100.
- 677 Kota, J., and Ljungdahl, P.O. (2005). Specialized membrane-localized chaperones prevent  
678 aggregation of polytopic proteins in the ER. *J Cell Biol 168*, 79-88.
- 679 Kuehn, M.J., Herrmann, J.M., and Schekman, R. (1998). COPII-cargo interactions direct  
680 protein sorting into ER-derived transport vesicles. *Nature 391*, 187-190.
- 681 Kuehn, M.J., Schekman, R., and Ljungdahl, P.O. (1996). Amino acid permeases require  
682 COPII components and the ER resident membrane protein Shr3p for packaging into  
683 transport vesicles in vitro. *J. Cell Biol. 135*, 585-595.
- 684 Lau, W.T., Howson, R.W., Malkus, P., Schekman, R., and O'Shea, E.K. (2000). Pho86p, an  
685 endoplasmic reticulum (ER) resident protein in *Saccharomyces cerevisiae*, is required for  
686 ER exit of the high-affinity phosphate transporter Pho84p. *Proc. Natl. Acad. Sci. USA 97*,  
687 1107-1112.
- 688 Ljungdahl, P.O., and Daignan-Fornier, B. (2012). Regulation of amino acid, nucleotide, and  
689 phosphate metabolism in *Saccharomyces cerevisiae*. *Genetics 190*, 885-929.  
690 10.1534/genetics.111.133306.
- 691 Ljungdahl, P.O., Gimeno, C.J., Styles, C.A., and Fink, G.R. (1992). SHR3: A novel component  
692 of the secretory pathway specifically required for the localization of amino acid  
693 permeases in yeast. *Cell 71*, 463-478.

- 694 Luo, W.J., Gong, X.H., and Chang, A. (2002). An ER membrane protein, Sop4, facilitates ER  
695 export of the yeast plasma membrane [H<sup>+</sup>]ATPase, Pma1. *Traffic* 3, 730-739.  
696 10.1034/j.1600-0854.2002.31005.x.
- 697 Madeira, F., Park, Y.M., Lee, J., Buso, N., Gur, T., Madhusoodanan, N., Basutkar, P., Tivey,  
698 A.R.N., Potter, S.C., Finn, R.D., and Lopez, R. (2019). The EMBL-EBI search and sequence  
699 analysis tools APIs in 2019. *Nucleic Acids Research* 47, W636-W641.  
700 <https://doi.org/10.1093/nar/gkz268>.
- 701 Malkus, P., Jiang, F., and Schekman, R. (2002). Concentrative sorting of secretory cargo  
702 proteins into COPII-coated vesicles. *J. Cell Biol.* 159, 915-921.
- 703 Martínez, P., and Ljungdahl, P.O. (2000). The SHR3 homologue from *S. pombe*  
704 demonstrates a conserved function of ER packaging chaperones. *J. Cell Sci.* 113, 4351-  
705 4362.
- 706 Martínez, P., and Ljungdahl, P.O. (2004). An ER packaging chaperone determines the  
707 amino acid uptake capacity and virulence of *Candida albicans*. *Mol Microbiol* 51, 371-384.
- 708 Miller, E., Antonny, B., Hamamoto, S., and Schekman, R. (2002). Cargo selection into COPII  
709 vesicles is driven by the Sec24p subunit. *EMBO J.* 21, 6105-6113.
- 710 Miller, E.A., Beilharz, T.H., Malkus, P.N., Lee, M.C., Hamamoto, S., Orci, L., and Schekman, R.  
711 (2003). Multiple cargo binding sites on the COPII subunit Sec24p ensure capture of  
712 diverse membrane proteins into transport vesicles. *Cell* 114, 497-509.
- 713 Miller-Vedam, L.E., Brauning, B., Popova, K.D., Schirle Oakdale, N.T., Bonnar, J.L., Prabu,  
714 J.R., Boydston, E.A., Sevillano, N., Shurtleff, M.J., Stroud, R.M., et al. (2020). Structural and  
715 mechanistic basis of the EMC-dependent biogenesis of distinct transmembrane clients.  
716 *Elife* 9. 10.7554/eLife.62611.
- 717 Nagamori, S., Smirnova, I.N., and Kaback, H.R. (2004). Role of YidC in folding of polytopic  
718 membrane proteins. *J. Cell Biol.* 165, 53-62.
- 719 O'Donnell, J.P., Phillips, B.P., Yagita, Y., Juszkievicz, S., Wagner, A., Malinverni, D., Keenan,  
720 R.J., Miller, E.A., and Hegde, R.S. (2020). The architecture of EMC reveals a path for  
721 membrane protein insertion. *Elife* 9. 10.7554/eLife.57887.
- 722 O'Keefe, S., and High, S. (2020). Membrane translocation at the ER: with a little help from  
723 my friends. *FEBS J.* 10.1111/febs.15309.
- 724 Ono, B.I., Ishino, Y., and Shinoda, S. (1983). Nonsense mutations in the can1 locus of  
725 *Saccharomyces cerevisiae*. *J Bacteriol* 154, 1476-1479.
- 726 Pleiner, T., Tomaleri, G.P., Januszyk, K., Inglis, A.J., Hazu, M., and Voorhees, R.M. (2020).  
727 Structural basis for membrane insertion by the human ER membrane protein complex.  
728 *Science* 369, 433-436. 10.1126/science.abb5008.
- 729 Rapoport, T.A., Li, L., and Park, E. (2017). Structural and Mechanistic Insights into Protein  
730 Translocation. *Annu Rev Cell Dev Biol* 33, 369-390. 10.1146/annurev-cellbio-100616-  
731 060439.

- 732 Risinger, A.L., Cain, N.E., Chen, E.J., and Kaiser, C.A. (2006). Activity-dependent reversible  
733 inactivation of the general amino acid permease. *Mol Biol Cell* *17*, 4411-4419.  
734 10.1091/mbc.e06-06-0506.
- 735 Rosell, A., Meury, M., Alvarez-Marimon, E., Costa, M., Perez-Cano, L., Zorzano, A.,  
736 Fernandez-Recio, J., Palacin, M., and Fotiadis, D. (2014). Structural bases for the  
737 interaction and stabilization of the human amino acid transporter LAT2 with its ancillary  
738 protein 4F2hc. *Proc Natl Acad Sci U S A* *111*, 2966-2971. 10.1073/pnas.1323779111.
- 739 Rytka, J. (1975). Positive selection of general amino acid permease mutants in  
740 *Saccharomyces cerevisiae*. *J Bacteriol* *121*, 562-570.
- 741 Saier, M.H., Jr. (2000). Families of transmembrane transporters selective for amino acids  
742 and their derivatives. *Microbiology* *146* ( Pt 8), 1775-1795. 10.1099/00221287-146-8-  
743 1775.
- 744 Schoebel, S., Mi, W., Stein, A., Ovchinnikov, S., Pavlovicz, R., DiMaio, F., Baker, D., Chambers,  
745 M.G., Su, H., Li, D., et al. (2017). Cryo-EM structure of the protein-conducting ERAD channel  
746 Hrd1 in complex with Hrd3. *Nature* *548*, 352-355. 10.1038/nature23314.
- 747 Seinen, A.B., and Driessen, A.J.M. (2019). Single-Molecule Studies on the Protein  
748 Translocon. *Annu Rev Biophys* *48*, 185-207. 10.1146/annurev-biophys-052118-115352.
- 749 Serdiuk, T., Balasubramaniam, D., Sugihara, J., Mari, S.A., Kaback, H.R., and Muller, D.J.  
750 (2016). YidC assists the stepwise and stochastic folding of membrane proteins. *Nat Chem*  
751 *Biol* *12*, 911-917. 10.1038/nchembio.2169.
- 752 Serdiuk, T., Steudle, A., Mari, S.A., Manioglu, S., Kaback, H.R., Kuhn, A., and Muller, D.J.  
753 (2019). Insertion and folding pathways of single membrane proteins guided by  
754 translocases and insertases. *Sci Adv* *5*, eaau6824. 10.1126/sciadv.aau6824.
- 755 Sherwood, P.W., and Carlson, M. (1999). Efficient export of the glucose transporter Hxt1p  
756 from the endoplasmic reticulum requires Gsf2p. *Proc. Natl. Acad. Sci. USA* *96*, 7415-7420.
- 757 Shurtleff, M.J., Itzhak, D.N., Hussmann, J.A., Schirle Oakdale, N.T., Costa, E.A., Jonikas, M.,  
758 Weibezahn, J., Popova, K.D., Jan, C.H., Sinitcyn, P., et al. (2018). The ER membrane protein  
759 complex interacts cotranslationally to enable biogenesis of multipass membrane proteins.  
760 *Elife* *7*. 10.7554/eLife.37018.
- 761 Silve, S., Volland, C., Garnier, C., Jund, R., Chevallerier, M.R., and Haguenaer-Tsapis, R.  
762 (1991). Membrane insertion of uracil permease, a polytopic yeast plasma membrane  
763 protein. *Mol. Cell. Biol.* *11*, 1114-1124.
- 764 Usami, Y., Uemura, S., Mochizuki, T., Morita, A., Shishido, F., Inokuchi, J., and Abe, F. (2014).  
765 Functional mapping and implications of substrate specificity of the yeast high-affinity  
766 leucine permease Bap2. *Biochim Biophys Acta* *1838*, 1719-1729.  
767 10.1016/j.bbamem.2014.03.018.
- 768 van't Klooster, J.S., Bianchi, F., Doorn, R.B., Lorenzon, M., Lusseveld, J.H., Punter, C.M., and  
769 Poolman, B. (2020). Extracellular loops matter - subcellular location and function of the  
770 lysine transporter Lyp1 from *Saccharomyces cerevisiae*. *FEBS J.* 10.1111/febs.15262.

- 771 Volkmar, N., and Christianson, J.C. (2020). Squaring the EMC - how promoting membrane  
772 protein biogenesis impacts cellular functions and organismal homeostasis. *J Cell Sci* 133.  
773 10.1242/jcs.243519.
- 774 Wagner, S., Pop, O.I., Haan, G.J., Baars, L., Koningstein, G., Klepsch, M.M., Genevaux, P.,  
775 Luirink, J., and de Gier, J.W. (2008). Biogenesis of MalF and the MalFGK(2) maltose  
776 transport complex in *Escherichia coli* requires YidC. *J Biol Chem* 283, 17881-17890.  
777 10.1074/jbc.M801481200.
- 778 Waterhouse, A.M., Procter, J.B., Martin, D.M., Clamp, M., and Barton, G.J. (2009). Jalview  
779 Version 2--a multiple sequence alignment editor and analysis workbench. *Bioinformatics*  
780 25, 1189-1191. 10.1093/bioinformatics/btp033.
- 781 Wong, F.H., Chen, J.S., Reddy, V., Day, J.L., Shlykov, M.A., Wakabayashi, S.T., and Saier, M.H.,  
782 Jr. (2012). The amino acid-polyamine-organocation superfamily. *J Mol Microbiol*  
783 *Biotechnol* 22, 105-113. 10.1159/000338542.
- 784 Zhu, L., Kaback, H.R., and Dalbey, R.E. (2013). YidC protein, a molecular chaperone for  
785 LacY protein folding via the SecYEG protein machinery. *J Biol Chem* 288, 28180-28194.  
786 10.1074/jbc.M113.491613.
- 787



788

789 **Figure 1. Scanning mutagenesis of the Shr3 membrane domain**

790 (A) Graphical representation of Shr3 topology and position of residues resulting in a non-functional protein. (B)

791 Top: Serial dilutions of cell suspensions from strain JKY2 (*shr3Δ*) carrying pRS316 (VC), pPL210 (*SHR3*), pAR4

792 (*shr3-35*), pAR18 (*shr3-50*) or pPL1349 (*shr3-76*) spotted on YPD and YPD+MM. The plates were incubated at

793 30 °C for 2 d and photographed. Bottom: Immunoblot analysis of Shr3 proteins in extracts prepared from the

794 strains; the levels of Pgk1 were used as loading controls. The blots were developed using α-Shr3 and α-Pgk1

795 antibodies. The signal intensities of the immunoreactive forms of Shr3 and Pgk1 were quantified, and the Shr3


796 signals were normalized with respect to Pgk1; the mean values are plotted, error bars show standard deviation

797 (n=3). (C) Serial dilutions of cell suspensions from strain JKY2 (*shr3Δ*) carrying pRS316 (VC), pPL210 (*SHR3*),

798 pAR4 (*shr3-35*), pPL1330 (*SHR3-36*), pAR47 (*shr3-37*), pAR37 (*SHR3-38*), pAR18 (*shr3-50*), pAR51 (*SHR3-*

799 *51*), pAR52 (*SHR3-52*), pAR50 (*shr3-53*), pPL1349 (*shr3-76*), pAR48 (*shr3-77*) or pAR49 (*SHR3-78*) spotted on

800 YPD and YPD+MM plates. Plates were incubated at 30 °C for 2 d and photographed.




801

802 **Figure 2. Deletion analysis of ER-lumen oriented loops**

803 (A) Graphical representation of Shr3 topology and the positions of the internal deletions in loops L1 and L3. (B)  
804 Based on structural predictions (Drozdetskiy et al., 2015), amino acid residues 44-57 in L1 are predicted to fold  
805 into an  $\alpha$ -helix with amphipathic character. Helical wheel projection of the L1  $\alpha$ -helix with non-polar (yellow),  
806 polar (grey), negatively- (blue) and positively-charged (red) residues indicated. (C) Serial dilutions of cell  
807 suspensions from strain JKY2 (*shr3Δ*) carrying pRS316 (VC), pPL210 (*SHR3*), pAR41 (*shr3Δ90*), pAR42  
808 (*shr3Δ91*), pAR43 (*shr3Δ92*), pAR44 (*shr3Δ93*) or pAR45 (*shr3Δ94*) spotted on SAD containing D-histidine (D-  
809 his), SD + L-canavanine (L-Can), SD + AzC, and YPD + MM plates. Plates were incubated at 30 °C for 2 d and  
810 photographed. Bottom: Immunoblot analysis of Shr3 proteins in extracts prepared from the strains; the levels of  
811 Dpm1 were used as loading controls. The blots were developed using  $\alpha$ -Shr3 and  $\alpha$ -Dpm1 antibodies. The signal  
812 intensities of the immunoreactive forms of Shr3 and Dpm1 were quantified, and the Shr3 signals were normalized  
813 with respect to Dpm1; the mean values are plotted, error bars show standard deviation (n=3).






814

815 **Figure 3. Mutational analysis of Shr3 function and substrate specificity**


816 (A) Summary of growth characteristics of JKY2 (*shr3Δ*) individually expressing 44 Shr3-mutant proteins. Cells  
 817 were spotted on media containing toxic amino analogues and nitrogen sources as follows: D-his, D-histidine (0.5%  
 818 w/v), allantoin; L-can, L-canavanine (1 μg/ml), ammonium; AzC, azetidine-2-carboxylate (1 mM), ammonium;  
 819 MM (200 μg/ml), yeast extract and peptone. Growth was scored after 2 - 3 d of incubation at 30 °C (Supplementary  
 820 Materials Fig. S1-S10). Colors reflect Shr3 function relative to wildtype activity: red, no function (-); orange, weak  
 821 but detectable function (+/-); yellow, intermediate function but less than wildtype (+); light blue, wildtype function  
 822 (WT); dark blue, enhanced function (WT<sup>+</sup>). (B) Clustal O (Madeira *et al.*, 2019) comparison of Shr3 sequences,  
 823 corresponding to aa residues 1-159 of *S. cerevisiae*, and orthologs of members from the *Saccharomyces sensu*  
 824 *stricto* group (*S. paradoxus*, *S. mikatae*) and orthologs from *sensu lato* fungi (*S. pombe*, *A. nidulans*, and *C.*  
 825 *albicans*). The consensus plot (identity; (Waterhouse *et al.*, 2009) and detailed multiple sequence alignments are  
 826 presented for the regions with mutations giving rise to major growth defects on selective media; identical residues  
 827 in three (light blue), four (blue), and five or six homologs (dark blue) are highlighted. (C) Shr3-dependent Ssy1  
 828 folding and function assessed by Stp1 processing. Immunoblot analysis of extracts from FGY135 (*shr3Δ*) carrying  
 829 pCA204 (*STP1-13xMYC*) and pRS316 (VC), pPL210 (*SHR3*), pAR004 (*shr3-35*), pAR45 (*SHR3Δ94*), pAR018  
 830 (*shr3-50*) or pPL1351 (*shr3-76*). Cells were grown in SD and induced 30 min with 1.3 mM leucine (+) as indicated.



831

832 **Figure 4. Assessing Shr3-Gap1 interactions using split ubiquitin**

833 (A) Schematic diagram of the split ubiquitin Shr3-NubA, shr3-35-NubA, Shr3Δ94-NubA and Gap1-Cub-GST  
 834 constructs. (B) Overview of the split-ubiquitin assay and expected outcomes. (C) Left panels: serial dilutions of  
 835 cell suspensions from strain JKY2 (*shr3Δ*) carrying pRS316 (VC), pPL210 (*SHR3*), pPL1262 (*SHR3-NubA*),  
 836 pAR67 (*shr3-35-NubA*) or pAR76 (*SHR3Δ94-NubA*) spotted on YPD and YPD+MM plates. Plates were incubated  
 837 at 30 °C for 2 d and photographed. Right panel: serial dilutions of cell suspensions from strain FGY15 (*gap1Δ*)  
 838 carrying pRS317 (VC), pJK92 (*GAP1*), pPL1257 (*GAP1-Cub-GST*) or pIM28 (*gap1-ERX<sub>AAA</sub>-Cub-GST*) were  
 839 spotted on minimal medium with 2 % galactose as carbon source and 1 mM L-citrulline as sole nitrogen source.  
 840 Plates were incubated for 7 d and photographed. (D) Strain FGY135 (*gap1Δ shr3Δ*) expressing *SHR3-NubA*  
 841 (pPL1262), *shr3-35-NubA* (pAR67) or *SHR3Δ94-NubA* (pAR76) and carrying pPL1257 (*GAP1-Cub-GST*) were  
 842 induced with 2% galactose for 1 h. Proteins extracts were prepared, separated by SDS-PAGE and analyzed by  
 843 immunoblotting using α-HA antibody. The signal intensities of the immunoreactive forms of full-length and  
 844 cleaved Gap1 were quantified. The fraction of split-ubiquitin cleavage was determined; the mean values plotted  
 845 with error bars showing standard deviation (n=3).



846

847 **Figure 5. Monitoring Shr3-AAP interactions *in vivo***

848 (A) Schematic diagram of the split ubiquitin constructs used to evaluate Shr3-AAP and Shr3-HXT interactions.

849 (B) Shr3-Agp1, Shr3-Gnp1 and Shr3-Bap2 interactions. (C) Shr3-Ssy1 interactions. (D) Shr3-Can1 and Shr3-

850 Lyp1 interactions. (E) Shr3-Hxt1 and Shr3-Gal2 interactions. Strain FGY135 (*gap1Δ shr3Δ*) expressing *SHR3-*

851 *NubA* (pPL1262), *shr3-35-NubA* (pAR67) or *SHR3Δ94-NubA* (pAR76) and carrying (B) pIM6 (*AGP1-Cub-GST*),

852 pIM17 (*GNP1-Cub-GST*), or pIM7 (*BAP2-Cub-GST*) or (C) pIM19 (*SSY1-Cub-GST*) or (D) pIM8 (*CAN1-Cub-*


853 *GST*) or pIM18 (*LYP1-Cub-GST*), or (E) pIM32 (*HXT1-Cub-GST*) or pIM33 (*GAL2-Cub-GST*) were induced with

854 2% galactose for 1 h. Proteins extracts were prepared, separated by SDS-PAGE and analyzed by immunoblotting

855 using  $\alpha$ -HA antibody. The signal intensities of the immunoreactive forms of full-length and cleaved Agp1, Gnp1,

856 Bap2, Ssy1, Can1, Lyp1, Hxt1 and Gal2 constructs were quantified. The fraction of split-ubiquitin cleavage was


857 determined; the mean values plotted with error bars showing standard deviation (n=3).



858

859 **Figure 6. Progressivity of Shr3-Gap1 chaperone-substrate interactions**


860 (A) Schematic diagram of split ubiquitin constructs including the gap1-Cub-GST, hxt1-Cub-GST and gal2-Cub-  
 861 GST truncation constructs. (B) Strain FGY135 (*gap1Δ shr3Δ*) carrying pPL1262 (*SHR3-NubA*) and pIM1 (*gap1-*  
 862 *2TM-Cub-GST*), pIM2 (*gap1-4TM-Cub-GST*), pIM3 (*gap1-6TM-Cub-GST*), pIM4 (*gap1-8TM-Cub-GST*), pIM5  
 863 (*gap1-10TM-Cub-GST*) or pIM16 (*gap1-12TM-Cub-GST*) (left panel), or pIM34 (*hxt1-2TM-Cub-GST*), pIM35  
 864 (*hxt1-4TM-Cub-GST*), pIM36 (*hxt1-6TM-Cub-GST*), pIM37 (*hxt1-8TM-Cub-GST*), pIM38 (*hxt1-10TM-Cub-*  
 865 *GST*) or pIM39 (*hxt1-12TM-Cub-GST*) (center panel) or pIM40 (*gal2-2TM-Cub-GST*), pIM41 (*gal2-4TM-Cub-*  
 866 *GST*), pIM42 (*gal2-6TM-Cub-GST*), pIM43 (*gal2-8TM-Cub-GST*), pIM44 (*gal2-10TM-Cub-GST*) or pIM45  
 867 (*gal2-12TM-Cub-GST*) (right panel) were induced with 2% galactose for 1 h. Extracts were prepared, separated  
 868 by SDS-PAGE and analyzed by immunoblotting using  $\alpha$ -HA antibody. (C) The signal intensities of the  
 869 immunoreactive forms of uncleaved Cub constructs and cleaved interaction marker (GST-6xHA) were quantified;  
 870 the mean values of the fraction of split ubiquitin cleavage is plotted with error bars showing standard deviation  
 871 (n=3).



872

873 **Figure 7. Progressive Shr3-Agp1 and Shr3-Ssy1 chaperone-substrate interactions**

874 (A) Schematic diagram of agp1-Cub-GST truncation constructs. Strain FGY135 (*gap1Δ shr3Δ*) expressing *SHR3-*  
 875 *NubA* (pPL1262) or *SHR3Δ94-NubA* (pAR76) and carrying pIM9 (*agp1-2TM-Cub-GST*), pIM10 (*agp1-4TM-Cub-*  
 876 *GST*), pIM11 (*agp1-6TM-Cub-GST*), pIM12 (*agp1-8TM-Cub-GST*), pIM13 (*agp1-10TM-Cub-GST*) or pIM26  
 877 (*agp1-12TM-Cub-GST*) were induced with 2% galactose for 1 h. Extracts were prepared, separated by SDS-PAGE  
 878 and analyzed by immunoblotting using  $\alpha$ -HA antibody. The signal intensities of the immunoreactive forms of  
 879 uncleaved Cub constructs and cleaved interaction marker (GST-6xHA) were quantified; the mean values of the  
 880 fraction of split ubiquitin cleavage is plotted with error bars showing standard deviation (n=3). (B) Schematic  
 881 diagram of ssy1-Cub-GST truncation constructs. Strain FGY135 (*gap1Δ shr3Δ*) expressing *SHR3-NubA*  
 882 (pPL1262) or *SHR3Δ94-NubA* (pAR76) and carrying pIM20 (*ssy1-2TM-Cub-GST*), pIM21 (*ssy1-4TM-Cub-GST*),  
 883 pIM22 (*ssy1-6TM-Cub-GST*), pIM23 (*ssy1-8TM-Cub-GST*), pIM24 (*ssy1-10TM-Cub-GST*) or pIM25 (*ssy1-*  
 884 *12TM-Cub-GST*) were induced with 2% galactose for 1 h. Extracts were prepared, and analyzed as in (A) and the  
 885 mean values of the fraction of split ubiquitin cleavage is plotted with error bars showing standard deviation (n=3).



886

887 **Figure 8. Model of Shr3 facilitated AAP folding**

888 Shr3 interacts transiently with AAP as they are co-translationally inserted into the ER membrane. Interactions start  
889 early, when 2-4MS have partitioned into the lipid bilayer, and continue until all MS are inserted. When AAP have  
890 fully integrated into the membrane and attain native conformations, the interactions with Shr3 diminish. The co-  
891 translational Shr3 function is specifically required for AAP folding and ER-exit. The chaperone activity depends  
892 on relatively few residues of the Shr3 sequence, suggesting that it functions as folding template. In the absence of  
893 Shr3, AAP are specifically retained in the ER and form high-molecular weight aggregates that are recognized as  
894 ERAD substrates.

895 **Supplementary Material**

896 **Figures:**

897 **Fig S1.** Growth-based assessment of Shr3 substrate specificity - I

898 **Fig S2.** Growth-based assessment of Shr3 substrate specificity - II

899 **Fig S3.** Growth-based assessment of Shr3 substrate specificity - III

900 **Fig S4.** Growth-based assessment of Shr3 substrate specificity - IV

901 **Fig S5.** Growth-based assessment of Shr3 substrate specificity - V

902 **Fig S6.** Growth-based assessment of Shr3 substrate specificity - VI

903 **Fig S7.** Growth-based assessment of Shr3 substrate specificity - VII

904 **Fig S8.** Growth-based assessment of Shr3 substrate specificity - VIII

905 **Fig S9.** Growth-based assessment of Shr3 substrate specificity - IX

906 **Fig S10.** Growth-based assessment of Shr3 substrate specificity - X

907 **Fig S11.** Effect of ER exit motif mutations on Shr3-AAP interactions

908 **Fig S12.** Protease cleavage assay to assess the topology of shr3-35-NubA and gap1-2TM-Cub-GST  
909 constructs

910 **Fig S13.** Interactions between Shr3-NubA and can1-8TM, -10TM-Cub-GST

911

912 **Tables:**

913 **Table S1.** Strains

914 **Table S2.** Plasmids